<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03904563</url>
  </required_header>
  <id_info>
    <org_study_id>GASTO-1046</org_study_id>
    <nct_id>NCT03904563</nct_id>
  </id_info>
  <brief_title>Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma</brief_title>
  <official_title>A Single-armed Phase Ⅱ Study of Bevacizumab Maintenance Therapy After Chemoradiotherapy for Locally Advanced Lung Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective phase II study is to determine the efficacy and safety of bevacizumab
      maintenance therapy after concurrent chemoradiotherapy in locally advanced lung
      adenocarcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective phase II study is to determine the efficacy and safety of bevacizumab
      maintenance therapy after concurrent chemoradiotherapy in locally advanced lung
      adenocarcinoma.

      All patients received 4 cycles of weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡)(DP), each
      of 1 day's duration, combined with split-course thoracic radiotherapy, with one-month
      break.Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The
      recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every
      3 weeks for 6 courses. Toxicities will be graded according to National Cancer Institute
      Common Terminology Criteria for Adverse Events (CTCAE) v. 4.0.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>Progression-free survival in patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of grade≥2 radiation pneumonia(NCI-CTC4.0)</measure>
    <time_frame>1 year from the end of chemoradiotherapy</time_frame>
    <description>radiation-induced pulmonary injury is classified into 1-5 grades according to NCI-CTC4.0. The incidence of symptomatic radiation-induced pulmonary injury: the ratio of grade 2 and above radiation-induced pulmonary injury cases in 1 year after radio therapy to all cases can be evaluated .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3-year</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of grade 3-4 radiation esophagitis</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of grade 3-4 radiation pneumonitis</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Lung Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients received four cycles of weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡)(DP), each of 1 day's duration, combined with split-course thoracic radiotherapy, with one-month break.Then every patients are treated with 6 courses of Bevacizumab 1-2 months later.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for 6 courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Every patients are treated with 6 courses of Bevacizumab 1-2 months after the chemoradiotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for 6 courses.</description>
    <arm_group_label>Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>chest radiation</intervention_name>
    <description>split-course chest radiation</description>
    <arm_group_label>Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>concurrent chemotherapy</intervention_name>
    <description>weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation</description>
    <arm_group_label>Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic confirmation of lung adenocarcinoma

          -  Patients have measurable or evaluable lesions based on the Response Evaluation
             Criteria in Solid Tumors (RECIST) criteria.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

          -  Unresectable, refusing surgery or after R2 surgery ,confirmed by PET-CT or chest and
             abdominal CT, craniocerebral MRI, and ECT.

          -  After radiotherapy and chemotherapy, the tumor is in partial remission, complete
             remission or stable.

          -  1-2 months after chemoradiotherapy ends.

          -  Organ and bone marrow functions were normal within the first 30 days of enrollment,
             including: • AST, ALT≤ 2.5*ULN or ≤5*ULN (with liver metastasis); • TBil ≤ 1.5 ULN •
             neutrophils absolute value ≥500 cells/mm3 • creatinine clearance ≥45 mL/min ;•
             platelets≥50,000 cells/mm3.

          -  CB6 within normal limits

          -  Patients and their family signed the informed consents

        Exclusion Criteria:

          -  Lung squamous carcinoma.

          -  The tumor has completely approached, encircled, or invaded the intravascular space of
             the great vessels (e.g., the pulmonary artery or the superior vena cava).

          -  The tumor was associated with a cavity over 2cm in diameter.

          -  Bleeding tendency or coagulation disorder.

          -  Patients with hemoptysis (1/2 teaspoon blood/day) within 1 month.

          -  Full-dose anticoagulation therapy was used within the past 1 month.

          -  Severe vascular disease occurred within 6 months.

          -  Gastrointestinal fistula, perforation or abdominal abscess occurred within 6 months.

          -  Hypertensive crisis, hypertensive encephalopathy, symptomatic heart failure (New York
             class II or above), active cerebrovascular disease or cardiovascular disease occurred
             within 6 months.

          -  Uncontrolled hypertension (systolic &gt; 150mmHg and/or diastolic &gt; 100mmHg).

          -  Major surgery within 28 days or minor surgery or needle biopsy within 48 hours.

          -  Urine protein 3-4+, or 24h urine protein quantitative &gt;1g.

          -  Degree 3 esophagitis after chemoradiotherapy has not recovered.

          -  Elderly patients (age 75 years).

          -  The investigator does not consider the participant to be eligible for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Liu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Qiu, Attending</last_name>
    <phone>+86-020-87343031</phone>
    <email>qiubo@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui liu, Professor</last_name>
    <phone>+86-020-87343031</phone>
    <email>liuhui@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Qiu, Attending</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.</citation>
    <PMID>25651787</PMID>
  </reference>
  <reference>
    <citation>Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015 Feb;16(2):187-99. doi: 10.1016/S1470-2045(14)71207-0. Epub 2015 Jan 16.</citation>
    <PMID>25601342</PMID>
  </reference>
  <reference>
    <citation>Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, Bogart JA, Dobelbower MC, Bosch W, Galvin JM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Raben A, Augspurger ME, MacRae RM, Paulus R, Bradley JD. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol. 2017 Jan;35(1):56-62. Epub 2016 Oct 31.</citation>
    <PMID>28034064</PMID>
  </reference>
  <reference>
    <citation>Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.</citation>
    <PMID>28885881</PMID>
  </reference>
  <reference>
    <citation>Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC, Chen M, Kim DW, Kim HK, Min YJ, Kang JH, Choi JH, Kim SW, Zhu G, Wu YL, Kim SR, Lee KH, Song HS, Choi YL, Sun JM, Jung SH, Ahn MJ, Park K. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. J Clin Oncol. 2015 Aug 20;33(24):2660-6. doi: 10.1200/JCO.2014.60.0130. Epub 2015 Jul 6.</citation>
    <PMID>26150444</PMID>
  </reference>
  <reference>
    <citation>Tsujino K, Kurata T, Yamamoto S, Kawaguchi T, Kubo A, Isa S, Hasegawa Y, Ou SH, Takada M, Ando M. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature. J Thorac Oncol. 2013 Sep;8(9):1181-9. doi: 10.1097/JTO.0b013e3182988348.</citation>
    <PMID>23883782</PMID>
  </reference>
  <reference>
    <citation>Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50. Erratum in: N Engl J Med. 2007 Jan 18;356(3):318.</citation>
    <PMID>17167137</PMID>
  </reference>
  <reference>
    <citation>Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009 Mar 10;27(8):1227-34. doi: 10.1200/JCO.2007.14.5466. Epub 2009 Feb 2. Erratum in: J Clin Oncol. 2009 May 10;27(14):2415.</citation>
    <PMID>19188680</PMID>
  </reference>
  <reference>
    <citation>Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015 Jul 1;33(19):2197-204. doi: 10.1200/JCO.2014.59.4424. Epub 2015 May 26.</citation>
    <PMID>26014294</PMID>
  </reference>
  <reference>
    <citation>Nadler E, Yu E, Ravelo A, Sing A, Forsyth M, Gruschkus S. Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network. Oncologist. 2011;16(4):486-96. doi: 10.1634/theoncologist.2010-0287. Epub 2011 Mar 25.</citation>
    <PMID>21441299</PMID>
  </reference>
  <reference>
    <citation>Gallet P, Phulpin B, Merlin JL, Leroux A, Bravetti P, Mecellem H, Tran N, Dolivet G. Long-term alterations of cytokines and growth factors expression in irradiated tissues and relation with histological severity scoring. PLoS One. 2011;6(12):e29399. doi: 10.1371/journal.pone.0029399. Epub 2011 Dec 22.</citation>
    <PMID>22216271</PMID>
  </reference>
  <reference>
    <citation>Wozniak AJ, Moon J, Thomas CR Jr, Kelly K, Mack PC, Gaspar LE, Raben D, Fitzgerald TJ, Pandya KJ, Gandara DR. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer. 2015 Sep;16(5):340-7. doi: 10.1016/j.cllc.2014.12.014. Epub 2015 Jan 9.</citation>
    <PMID>25703100</PMID>
  </reference>
  <reference>
    <citation>Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N, Farley C, Burris HA 3rd, Greco FA. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol. 2010 Jan 1;28(1):43-8. doi: 10.1200/JCO.2009.24.7353. Epub 2009 Nov 9.</citation>
    <PMID>19901100</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hui Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>bevacizumab</keyword>
  <keyword>Split-course Chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

